Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load

AIDS

Volumn 26, Issue 13, 2012, Pages 1726-1728

  Pasquet, Armelle ^a   Ajana, Faiza ^a   Melliez, Hugues ^a   Giurca, Caius ^a   Poissy, Julien ^a   Yazdanpanah, Yazdan ^a  

^a CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

AGED; ANEMIA; CASE REPORT; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DURA MATER; FEMALE; HEADACHE; HIV RELATED PACHYMENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; MENINGITIS; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; WHITE MATTER;

AGED; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MAGNETIC RESONANCE IMAGING; MENINGITIS, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865483161     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835646fb     Document Type: Letter

References (19)

1. Kupersmith MJ, Martin V, Heller G, Shah A, Mitnick HJ. Idiopathic hypertrophic pachymeningitis. Neurology 2004; 62:686-694. (Pubitemid 38298941)
2. Shobha N, Mahadevan A, Taly AB, Sinha S, Srikanth SG, Satish S, et al. Hypertrophic cranial pachymeningitis in countries endemic for tuberculosis: diagnostic and therapeutic dilemmas. J Clin Neurosci 2008; 15:418-427.
3. Wang YJ, Fuh JL, Lirng JF, Lu SR, Wang SJ. Headache profile in patients with idiopathic hypertrophic cranial pachymeningitis. Headache 2004; 44:916-923.
4. Okuma H, Kobori S, Shinohara Y, Takagi S. A case of hypertrophic pachymeningitis with prolonged headache, attributable to Epstein-Barr virus. Headache 2007; 47:620-622. (Pubitemid 46625270)
5. B Best, S Letendre, D Croteau, E Capparelli, D Clifford, B Gelman, et al. Therapeutic DRV and ETR Concentrations in Cerebrospinal Fluid. Abs 643; CROI 2011.
6. Calcagno A, Bonora S, Bertucci R, Lucchini A, D'Avolio A, Di Perri G. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. AIDS 2010; 24:931-932.
7. Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percentage inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother 2010; 54:5156-5160.
8. Melica G, Canestri A, Peytavin G, Lelievre JD, Bouvier-Alias M, Clavel C, et al. Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms. AIDS 2010; 24:2130-2133.
9. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773-778.
10. Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 2011; 8:54-61.
11. Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR. Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother 2011; 66:1954-1962.
12. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis; 2010; 50:773-778.
13. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
14. S Letendre, C FitzSimons, R Ellis, D Clifford, A Collier, B Gelman, et al. Correlates of CSF Viral Loads in 1,221 Volunteers of the CHARTER Cohort. Abs 172; CROI 2011.
15. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, et al. Dynamics of cognitive change in impaired HIVpositive patients initiating antiretroviral therapy. Neurology 2009; 73:342-348.
16. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25:357-365.
17. Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010; 50:920-929.
18. Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24:2347-2354.
19. de Truchis P, Mathez D, Abe E, Dinh A, Ledu D, Greder-Belan A, et al. Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy. AIDS 2010; 24:1235-1236.